organization · Reporting owner
Eclipse Acquisition Corp.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ICAGEN INCICGN · Entity 13934 | 10% owner | October 27, 2011 | November 02, 2011 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100 |
Reported balance
After 2011-10-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2011-10-27 · Purchase · Acquired 2,743,269 · Balance 100 F1: This amount reflects all of the outstanding shares of Icagen, Inc. ("Icagen") not owned by Pfizer Inc. ("Pfizer") and Eclipse Acquisition Corp. On October 27, 2011, Eclipse Acquisition Corp. was merged with and into Icagen with Icagen continuing as the surviving corporation and a wholly-owned subsidiary of Pfizer. At the effective time of the merger, these shares of common stock were cancelled and ceased to exist. F2: Prior to the merger, Pfizer held 100 shares of common stock, $0.01 par value per share, of Eclipse Acquisition Corp., which represented all of the issued and outstanding capital stock of Eclipse Acquisition Corp. At the effective time of the merger, each share of Eclipse Acquisition Corp. was converted into one share of common stock of Icagen, resulting in the acquisition by Pfizer of 100% of the equity interest of Icagen. |
Filing footnotes · ownership attribution and instrument terms
F1: This amount reflects all of the outstanding shares of Icagen, Inc. ("Icagen") not owned by Pfizer Inc. ("Pfizer") and Eclipse Acquisition Corp. On October 27, 2011, Eclipse Acquisition Corp. was merged with and into Icagen with Icagen continuing as the surviving corporation and a wholly-owned subsidiary of Pfizer. At the effective time of the merger, these shares of common stock were cancelled and ceased to exist.
F2: Prior to the merger, Pfizer held 100 shares of common stock, $0.01 par value per share, of Eclipse Acquisition Corp., which represented all of the issued and outstanding capital stock of Eclipse Acquisition Corp. At the effective time of the merger, each share of Eclipse Acquisition Corp. was converted into one share of common stock of Icagen, resulting in the acquisition by Pfizer of 100% of the equity interest of Icagen.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 27, 2011 Filed Nov 2, 2011 23:16 UTC | ICAGEN INC ICGN · Entity 13934 | PurchaseCommon Stock | 2,743,269 | $6.00 | $16,459,614.00 |
DisclosureSEC source: 0000078003-11-000018 · primary_doc.xml · nonDerivative · entry 1 PFIZER INC · CIK 0000078003 · 10% owner Eclipse Acquisition Corp. · CIK 0001529320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · shares: This amount reflects all of the outstanding shares of Icagen, Inc. ("Icagen") not owned by Pfizer Inc. ("Pfizer") and Eclipse Acquisition Corp. On October 27, 2011, Eclipse Acquisition Corp. was merged with and into Icagen with Icagen continuing as the surviving corporation and a wholly-owned subsidiary of Pfizer. At the effective time of the merger, these shares of common stock were cancelled and ceased to exist. F2 · balance_after: Prior to the merger, Pfizer held 100 shares of common stock, $0.01 par value per share, of Eclipse Acquisition Corp., which represented all of the issued and outstanding capital stock of Eclipse Acquisition Corp. At the effective time of the merger, each share of Eclipse Acquisition Corp. was converted into one share of common stock of Icagen, resulting in the acquisition by Pfizer of 100% of the equity interest of Icagen. Read SEC document |
| September 19, 2011 Filed Sep 20, 2011 19:06 UTC | ICAGEN INC ICGN · Entity 13934 | PurchaseCommon Stock | 61,083 | $6.00 | $366,498.00 |
DisclosureSEC source: 0000078003-11-000017 · primary_doc.xml · nonDerivative · entry 2 PFIZER INC · CIK 0000078003 · 10% owner Eclipse Acquisition Corp. · CIK 0001529320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · FN Disclosed balance after: 5,393,380 F1 · ownership.nature: Shares are directly owned by Eclipse Acquisition Corp., a wholly owned subsidiary of Pfizer Inc. Read SEC document |
| September 16, 2011 Filed Sep 20, 2011 19:06 UTC | ICAGEN INC ICGN · Entity 13934 | PurchaseCommon Stock | 5,536 | $6.00 | $33,216.00 |
DisclosureSEC source: 0000078003-11-000017 · primary_doc.xml · nonDerivative · entry 1 PFIZER INC · CIK 0000078003 · 10% owner Eclipse Acquisition Corp. · CIK 0001529320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · FN Disclosed balance after: 5,332,297 F1 · ownership.nature: Shares are directly owned by Eclipse Acquisition Corp., a wholly owned subsidiary of Pfizer Inc. Read SEC document |
| September 15, 2011 Filed Sep 16, 2011 22:01 UTC | ICAGEN INC ICGN · Entity 13934 | PurchaseCommon Stock | 232,203 | $6.00 | $1,393,218.00 |
DisclosureSEC source: 0000078003-11-000016 · primary_doc.xml · nonDerivative · entry 1 PFIZER INC · CIK 0000078003 · 10% owner Eclipse Acquisition Corp. · CIK 0001529320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · FN Disclosed balance after: 5,326,761 F1 · ownership.nature: Shares are directly owned by Eclipse Acquisition Corp., a wholly owned subsidiary of Pfizer Inc. Read SEC document |
| September 12, 2011 Filed Sep 14, 2011 23:25 UTC | ICAGEN INC ICGN · Entity 13934 | PurchaseCommon Stock | 422,023 | $6.00 | $2,532,138.00 |
DisclosureSEC source: 0000078003-11-000013 · primary_doc.xml · nonDerivative · entry 1 PFIZER INC · CIK 0000078003 · 10% owner Eclipse Acquisition Corp. · CIK 0001529320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · FN Disclosed balance after: 5,094,558 F1 · ownership.nature: Shares are directly owned by Eclipse Acquisition Corp., a wholly owned subsidiary of Pfizer Inc. Read SEC document |
| September 09, 2011 Filed Sep 12, 2011 17:27 UTC | ICAGEN INC ICGN · Entity 13934 | PurchaseCommon Stock | 60,121 | $6.00 | $360,726.00 |
DisclosureSEC source: 0000078003-11-000012 · primary_doc.xml · nonDerivative · entry 2 PFIZER INC · CIK 0000078003 · 10% owner Eclipse Acquisition Corp. · CIK 0001529320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · FN Disclosed balance after: 4,677,659 F1 · ownership.nature: Shares are directly owned by Eclipse Acquisition Corp., a wholly owned subsidiary of Pfizer Inc. Read SEC document |
| September 08, 2011 Filed Sep 12, 2011 17:27 UTC | ICAGEN INC ICGN · Entity 13934 | PurchaseCommon Stock | 493 | $6.00 | $2,958.00 |
DisclosureSEC source: 0000078003-11-000012 · primary_doc.xml · nonDerivative · entry 1 PFIZER INC · CIK 0000078003 · 10% owner Eclipse Acquisition Corp. · CIK 0001529320 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · FN Disclosed balance after: 4,617,538 F1 · ownership.nature: Shares are directly owned by Eclipse Acquisition Corp., a wholly owned subsidiary of Pfizer Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.